Rational use of moxifloxacin for tuberculosis treatment

Hdl Handle:
http://hdl.handle.net/10144/129952
Title:
Rational use of moxifloxacin for tuberculosis treatment
Authors:
Cox, Helen; Ford, Nathan; Keshavjee, Salmaan; McDermid, Cheryl; von Schoen-Angerer, Tido; Mitnick, Carole; Goemaere, Eric
Journal:
The Lancet Infectious Diseases
Affiliation:
Burnet Institute, Melbourne, Australia; Médecins Sans Frontières, Johannesburg, South Africa; Centre for Infectious Disease Epidemiology and Research, University of Cape Town, South Africa; Harvard Medical School, Boston, USA; Partners in Health, Boston, USA; Médecins Sans Frontières Campaign for Access to Essential Medicines, Geneva, Switzerland
Issue Date:
1-Apr-2011
URI:
http://hdl.handle.net/10144/129952
DOI:
10.1016/S1473-3099(11)70036-6
PubMed ID:
21453864
Additional Links:
http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(11)70036-6/fulltext?_eventId=login
Submitted date:
2011-04-29
Type:
Article
Language:
en
ISSN:
1474-4457
Appears in Collections:
TB

Full metadata record

DC FieldValue Language
dc.contributor.authorCox, Helenen
dc.contributor.authorFord, Nathanen
dc.contributor.authorKeshavjee, Salmaanen
dc.contributor.authorMcDermid, Cherylen
dc.contributor.authorvon Schoen-Angerer, Tidoen
dc.contributor.authorMitnick, Caroleen
dc.contributor.authorGoemaere, Ericen
dc.date.accessioned2011-05-23T19:38:52Z-
dc.date.available2011-05-23T19:38:52Z-
dc.date.issued2011-04-01-
dc.date.submitted2011-04-29-
dc.identifier.citationLancet Infect Dis 2011;11(4):259-60en
dc.identifier.issn1474-4457-
dc.identifier.pmid21453864-
dc.identifier.doi10.1016/S1473-3099(11)70036-6-
dc.identifier.urihttp://hdl.handle.net/10144/129952-
dc.language.isoenen
dc.relation.urlhttp://www.thelancet.com/journals/laninf/article/PIIS1473-3099(11)70036-6/fulltext?_eventId=loginen
dc.rightsPublished by Elsevier Reproduced on this site with permission of Elsevier Ltd. Please see [url]http://www.thelancet.com/journals/laninf[/url] for further relevant comment.en
dc.subject.meshTuberculosisen
dc.subject.meshTuberculosis, Multidrug-Resistanten
dc.subject.meshMoxifloxacinen
dc.titleRational use of moxifloxacin for tuberculosis treatmenten
dc.typeArticleen
dc.contributor.departmentBurnet Institute, Melbourne, Australia; Médecins Sans Frontières, Johannesburg, South Africa; Centre for Infectious Disease Epidemiology and Research, University of Cape Town, South Africa; Harvard Medical School, Boston, USA; Partners in Health, Boston, USA; Médecins Sans Frontières Campaign for Access to Essential Medicines, Geneva, Switzerlanden
dc.identifier.journalThe Lancet Infectious Diseasesen

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.